Harrow health, inc. (IMMY)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
CASH FLOWS FROM OPERATING ACTIVITIES
Total net (loss) income including noncontrolling interests

-125

14,625

-

-

-

-

-

-

-

-

Net income (loss) attributable to Harrow Health, Inc.

-

-

-11,985

-19,087

-15,899

-10,118

-7,643

-5,383

-953

-2,531

Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization of property, plant and equipment

1,936

1,608

1,401

1,055

255

37

-

-

-

-

Estimated fair value of contributed services

-

-

-

-

-

-

-

0

0

0

Gain on forgiveness of liabilities

-

-

-

-

-

-

-

0

60

-

Amortization of prepaid consulting fees

-

-

-

-

-

-

-

0

0

235

Depreciation and amortization of furniture and equipment

-

-

-

-

-

-

5

2

0

1

Amortization of intangible assets

209

235

364

351

355

48

0

-

-

-

Amortization of operating lease right-of-use assets

518

-

-

-

-

-

-

-

-

-

Deferred income taxes

-

-

-935

-

-

-

-

-

-

-

Non-cash gain on contingent acquisition obligation

-

-

-

83

-

-

-

-

-

-

Amortization of debt issuance costs and discount

512

613

978

-

-

-

-

-

-

-

Deferred income taxes

-

-

-

-111

-

-

-

-

-

-

Amortization of deferred tax liability

-

-

-

-

0

-

-

-

-

-

Amortization of debt issuance costs and discount

-

-

-

970

281

0

-

-

-

-

Impairment of long-lived assets

-

-

-

-

0

-

-

-

-

-

Debt extinguishment

-

-

884

-1,966

-

-

-

-1,195

0

26

Debt extinguishment

-

-

-

-

0

-

-

-

-

-

Paid-in-kind interest added to principal of note payable

-

-

-

203

130

0

-

-

-

-

Gain on deconsolidation

-

-

-

0

-

-

-

-

-

-

Investment loss

-

-

-

0

-

-

-

-

-

-

Gain on sale and disposal of assets

-4,148

-393

-354

0

-

-

-

-

-

-

Stock-based payment of consulting services

234

150

-

-

-

-

-

-

-

-

Non-cash gain on contingent acquisition obligations

-

-

-

-

31

0

-

-

-

-

Change in fair value of derivative liabilities

-

-

-

113

0

-

-

-

-

-

Impairment of long-lived assets

-

-

-

303

-

-

-

-

-

-

Non-cash interest on notes payable

-

-

-

-

-

-

-

24

75

55

Stock-based compensation

1,789

2,486

2,943

3,673

3,441

2,615

3,134

2,156

192

680

Issuance of warrant related to litigation settlement

-

-

-

115

0

-

-

-

-

-

Changes in assets and liabilities:
Accounts receivable

95

384

-1,392

2,081

360

23

0

-

-

-

Inventories

2,271

-415

821

429

314

160

0

-

-

-

Prepaid consulting costs

-

-

-

-

-

-

-

-

0

0

Prepaid expenses and other current assets

471

123

-274

152

545

132

16

-46

45

20

Accounts payable and accrued expenses

1,342

2,365

346

1,515

1,028

345

-239

231

144

-

Accounts payable

-

-

-

-

-

-

-

-

-

-607

Accrued Phase 3 expenses

-

-

-

-

-

-

-

-

0

-231

Accrued payroll and related liabilities

-166

1,074

-429

438

453

342

320

18

-9

25

Deferred revenue and customer deposits

-62

90

-62

-

-

-

-

-

-

-

Deferred revenue and customer deposits

-

-

-

26

63

-11

0

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-100

20

80

NET CASH USED IN OPERATING ACTIVITIES

950

687

-8,803

-11,215

-11,143

-7,057

-4,438

-1,900

-291

-2,298

CASH FLOWS FROM INVESTING ACTIVITIES
Repayment of note receivable

-

4

-

-

-

-

-

-

-

-

Proceeds on sale and disposal of assets

4

-

113

-

-

-

-

-

-

-

Proceeds on sale and disposal of assets

-

-

-

0

-

-

-

-

-

-

Payments on Pharmacy Creations contingent acquisition obligation

-

-

-

100

-

-

-

-

-

-

Purchase of restricted short-term investments

-

-

-

-

-

-

50

-

-

-

Purchase of restricted short-term investments

-

-

-

-

-

-

-

0

-

-

Purchase of Park Compounding, net of cash

-

-

-

-

3,005

0

0

-

-

-

Purchase of Central Allen Pharmacy, net of cash

-

-

-

-

421

0

-

-

-

-

Purchase of assets for ImprimisRx PA, Inc.

-

-

-

-

-524

0

-

-

-

-

Payments on Pharmacy Creations contingent acquisition obligation

-

-

-

-

0

-

-

-

-

-

Investment in restricted marketable securities

-

-

-

50

0

-

-

-

-

-

Purchase of restricted short-term investment

-

-

-

-

-

100

-

-

-

-

Purchase of Pharmacy Creations, LLC, net of cash and advances

-

-

-

-

-

-636

-

-

-

-

Investment in patent and trademark assets

369

435

252

252

185

0

-

-

-

-

Purchase of Klarity license

-

-

50

-

-

-

-

-

-

-

Purchase of Klarity license

-

-

-

0

-

-

-

-

-

-

Purchases of property, plant and equipment

1,468

1,768

772

6,887

-995

174

20

15

0

0

NET CASH USED IN INVESTING ACTIVITIES

-1,833

-2,199

-961

-7,289

-5,130

-910

-70

-15

0

0

CASH FLOWS FROM FINANCING ACTIVITIES
Payments on finance lease obligations

743

691

-

-

-

-

-

-

-

-

Payments on capital lease obligations

-

-

626

267

25

10

0

-

-

-

Net proceeds from public equity offering

-

-

2,940

11,088

0

-

-

-

-

-

Net proceeds from private placement equity offering

-

-

-

9,217

0

-

-

-

-

0

Cancelled common stock

-

-

-

-

-

-13

0

0

-

-

Payments on Park deferred acquisition obligation

-

53

206

195

135

0

-

-

-

-

Proceeds from SWK debt, net of costs

-

-

15,518

0

-

-

-

-

-

-

Principal payments, exit fee and other costs of LSAF debt

-

-

-

0

-

-

-

-

-

-

Principal payments on note payable

750

-

13,999

-

-

-

-

-

-

-

Payments of costs related to amendment of note payable

282

-

-

-

-

-

-

-

-

-

Proceeds from note payable, net of issuance costs

-

-

-

-

9,265

0

-

-

-

-

Proceeds from convertible note payable, net of issuance costs

-

-

-

2,772

0

-

-

-

-

-

Proceeds from Essex leaseback, net of issuance costs

-

-

-

1,933

-

-

-

-

-

-

Proceeds from Essex leaseback, net of issuance costs

-

-

-

-

0

-

-

-

-

-

Net proceeds from ATM sales of common stock

-

642

1,124

212

404

0

10,052

11,504

0

-

Net proceeds from exercise of warrants and stock options, net of taxes remitted for RSU's and options

769

4,233

-

-

-

-

-

-

-

-

Proceeds from issuance of notes payable to a related party

-

-

-

-

-

-

-

450

300

0

Proceeds received in connection with debt modification

-

-

-

-

-

-

-

50

0

-

Proceeds from issuance of preferred stock

-

-

-

-

-

-

-

0

100

0

Proceeds from notes payable

-

-

-

-

-

-

-

0

0

1,000

Preferred stock deemed dividend paid at conversion

-

-

-

-

-

-

-

-200

0

-

Cash advances to and from related parties

-

-

-

-

-

-

-

0

254

0

Cash advances from related party

-

-

-

-

-

-

-

0

27

0

Repayment of advances from related party

-

-

-

-

-

-

-

0

281

0

Capital contributions

-

-

-

-

-

-

-

0

0

0

Net proceeds from exercise of warrants

-

-

179

-88

1,238

622

0

0

0

0

Payments for deferred offering costs

-

-

-

-

-

0

-

-

-

-

Deferred offering costs

-

-

-

-

-

-

-

-

0

-

NET CASH USED IN FINANCING ACTIVITIES

-1,006

4,131

4,930

24,672

10,747

599

10,052

11,805

145

1,000

NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

-1,889

2,619

-4,834

-

-

-

-

-

-

-

NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

-

-

-

6,168

-5,526

-7,368

5,543

9,889

-145

-1,298

RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH
Cash and cash equivalents

4,749

6,638

4,019

-

-

-

-

-

-

-

Restricted cash

200

200

200

-

-

-

-

-

-

-

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes

17

4

9

9

1

1

1

-

-

-

Cash paid for interest

1,967

2,097

1,543

1,366

-

-

-

-

-

-

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Purchase of property and equipment included in accounts payable

39

-

-

-

-

-

-

-

-

-

Right-of-use asset obtained in exchange for lease obligation

753

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

637

4

0

-

-

-

Cash paid for income taxes

-

-

-

-

-

-

-

1

2

-

Fair value of embedded conversion feature recorded as debt discount and derivative liability

-

-

-

2,322

0

-

-

-

-

-

Reclassification of the fair value of the embedded conversion feature derivative liability to additional paid-in capital upon closing of the public equity offering

-

-

-

2,646

0

-

-

-

-

-

Reclassification of the fair value of the LSAF warrant from additional paid-in capital to derivative liability

-

-

-

675

0

-

-

-

-

-

Reclassification of the fair value of the LSAF warrant derivative liability to additional paid-in capital upon closing of the public equity offering

-

-

-

464

0

-

-

-

-

-

Reduction in value of warrant in connection with debt extinguishment

-

-

-

73

0

-

-

-

-

-

Issuance of common stock to settle contingent acquisition obligation related to the purchase of PC

-

-

-

302

-

-

-

-

-

-

Relative fair value of warrants issued in connection with note payable

-

-

-

-

-

0

-

-

-

-

Issuance of common stock and fair value of deferred acquisition obligations related to the purchase of Park Compounding

-

-

-

-

1,016

0

-

-

-

-

Issuance of common stock and to settle contingent acquisition obligation related to the purchase of PC

-

-

-

-

0

-

-

-

-

-

Issuance of stock and stock options for consulting services included in accounts payable and accrued expenses

-

-

-

23

39

0

-

-

-

-

Final fee on note payable recorded as debt discount and included in accrued expenses

-

-

800

0

-

0

-

-

-

-

Estimated relative fair value of warrants issued in connection with note payable

-

-

982

-

-

-

-

-

-

-

Final fee on notes payable recorded as debt discount and included in accrued expenses

-

-

-

-

500

-

-

-

-

-

Estimated relative fair value of warrants issued in connection with note payable

-

-

-

0

840

-

-

-

-

-

Issuance of and adjustment to common stock and warrants to consulting firms for prepaid consulting fees

-

-

-

-

-

-

319

0

0

0

Deferred offering costs in connection with equity offering recorded in account payable

-

-

-

-

-

-

-

185

-

-

Deferred offering costs in connection with equity offering recorded in accounts payable

-

-

-

-

-

-

-

-

0

-

Conversion of related party accounts payable into common stock

-

-

-

-

-

-

-

56

0

-

Conversion of notes payable and accrued interest into common stock

-

-

-

-

-

-

-

1,905

-

0

Forgiveness of notes payable and accrued interest to shareholders

-

-

-

-

-

-

-

0

-

-

Conversion of notes payable and accrued interest into common stock

-

-

-

-

-

-

-

-

0

-

Forgiveness of notes payable and accrued interest to shareholders

-

-

-

-

-

-

-

-

0

0

Conversion of advances to notes payable to shareholders

-

-

-

-

-

-

-

0

0

0

Accretion of preferred stock discount

-

-

-

-

-

-

-

0

-100

0

Related party acquisition of Phase 3 liabilities

-

-

-

-

-

-

-

0

56

0

Conversion of preferred stock into common stock

-

-

-

-

-

-

-

1

0

-

Reclassification of deferred offering costs in connection with equity offering

-

-

-

-

-

-

596

0

-

-

Issuance of common stock for consulting services included in accounts payable and accrued expenses

-

-

-

-

-

-

139

0

-

-

Purchase of furniture and equipment with a capital lease

-

-

-

-

-

35

0

-

-

-

Purchase of property, plant and equipment included in accounts payable and accrued expenses

-

-

-

81

1,275

0

-

-

-

-

Note receivable in connection with sale of assets

-

-

410

0

-

-

-

-

-

-

Eton Pharmaceuticals [Member]
Investment (loss) gain, net

3,780

17,913

-

-

-

-

-

-

-

-

Investment gain from and equity in net loss

-

-

3,507

-

-

-

-

-

-

-

Surface Pharmaceuticals [Member]
Investment (loss) gain, net

-1,200

4,947

-

-

-

-

-

-

-

-

Melt Pharmaceuticals [Member]
Investment (loss) gain, net

3,968

-

-

-

-

-

-

-

-

-